FDA Warning Issued March 4, 2011
"New data suggest that the drug Topamax (topiramate) and its generic versions increase the risk for the birth defects cleft lip and cleft palate in babies born to women using the drug when they become pregnant or use the medication during pregnancy," the U.S. Food and Drug Administration said today.
"Health care professionals should carefully consider the benefits and risks of topiramate when prescribing it to women of childbearing age," said Russell Katz, M.D., director of the Division of Neurology Products in the FDA's Center for Drug Evaluation and Research. Alternatives should be considered.
For more information on Topamax Side Effects and safe alternative of migraine prevention, see www.Tuliv.com.
NOTE: Please forward this warning to friends who are taking Topamax.
See Full FDA Report at www.FDA.gov
